Cong Wang1 
,
Guannan Zhang2,
Jingru Wang2,
Wendong Zhang2,
Yu Zhang2,
Yatong Gu2
For correspondence:- Cong Wang Email: huyingtui469104846@163.com
Accepted: 5 May 2024 Published: 29 May 2024
Citation: Wang C, Zhang G, Wang J, Zhang W, Zhang Y, Gu Y. Clinical effect of suspension training and Mulligan technique in combination with celecoxib in the treatment of chronic non-specific lower back pain. Trop J Pharm Res 2024; 23(5):903-909 doi: 10.4314/tjpr.v23i5.13
© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the clinical efficacy of suspension training and Mulligan technique in combination with celecoxib in the management of chronic lower back ache of unknown causes.
Methods: A total of 100 subjects with persistent lower back pain of unknown etiology treated in the Sports Medical Rehabilitation Center, Shijiazhuang, China from June 2019 to December 2020, were assigned at random to control and study cohorts (n = 50/group). Celecoxib (100 to 200 mg/day) was taken orally, once or twice daily by the control cohort, while the other cohort received suspension training, Mulligan technology (once a day, 8 weeks) and celecoxib. The treatment effect, pain and dysfunction scores, inflammatory indicators, quality of life, and complications were compared on Visual Analogue Scale (VAS) and Oswestry Disability Index (ODI).
Results: The effect of Macnab standard in study group was significantly better than that in control group (p < 0.05). After treatment, VAS and ODI scores in both cohorts were significantly lower than pre-treatment values, but were significantly lesser in the study cohort. Furthermore, TNF-α level, and levels of CRP and IL-6 were significantly reduced when compared with pre-treatment levels, and were significantly lower in study cohort. The GQOL-74 scores in both groups were significantly increased after treatment, but were significantly lower in the control cohort (p < 0.05). No significant variations were seen in cases of complications between both cohorts.
Conclusion: The use of suspension training and Mulligan technology in combination with celecoxib in treating persistent lower back pain of unknown cause is beneficial in reducing lower back pain, mitigating dysfunction, and improving patients' quality of life. There is however a need for more studies to validate these findings.
Archives
News Updates
Fulltext in PDF